Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001465" target="_blank" >RIV/00064190:_____/25:10001465 - isvavai.cz</a>

Alternative codes found

RIV/61383082:_____/25:00001526 RIV/00216224:14110/25:00143502 RIV/00216208:11110/25:10498424 RIV/00216208:11130/25:10498424 RIV/00064203:_____/25:10498424

Result on the web

<a href="https://doi.org/10.1155/proc/1468262" target="_blank" >https://doi.org/10.1155/proc/1468262</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/proc/1468262" target="_blank" >10.1155/proc/1468262</a>

Result language

angličtina

Original language name

Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer

Original language description

Background: Abiraterone acetate is an androgen-receptor pathway inhibitor commonly used for treatment of metastatic prostate cancer. The levels of androgens during treatment with abiraterone acetate with prednisone (AAP) are lower than those achieved by androgen-deprivation therapy only, potentially resulting in a high risk of skeletal muscle loss. Methods: The cohort included 43 patients treated with AAP for metastatic hormone-sensitive prostate cancer or metastatic castration-resistant prostate cancer. To detect and quantify sarcopenia, we utilized standard computer tomography (CT) imaging. Skeletal muscle mass index (SMI) was evaluated by assessing two adjacent axial sections at the level of the L3 vertebra. Results: Sarcopenia at the time of AAP initiation was present in 72.1% of patients. Body mass index (BMI) was inversely associated with the presence of sarcopenia at the time of AAP initiation. There was a statistically significant decrease in SMI over AAP treatment. Age &gt; 75 years and the absence of previous radiotherapy were associated with a higher rate of SMI decrease during AAP therapy. Overall and progression-free survival was not significantly associated with SMI decrease during AAP therapy. Conclusions: SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy. Copyright (C) 2025 Eva Streckova et al. Prostate Cancer published by John Wiley &amp; Sons Ltd.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Prostate Cancer

ISSN

2090-3111

e-ISSN

—

Volume of the periodical

2025

Issue of the periodical within the volume

1

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

nestránkováno

UT code for WoS article

001490449800001

EID of the result in the Scopus database

2-s2.0-105005777804